Vivani Medical, Inc.(VANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VANI Vivani Medical, Inc.

Post-Mkt 06-15 19:28:21 EDT

1.13

+0.03

+2.73%

盘后1.17

+0.04+3.54%

19:15 EDT

High1.19	Low1.10	Vol214.34K
Open1.17	D1 Closing1.10	Amplitude8.18%
Mkt Cap97.45M	Tradable Cap41.66M	Total Shares86.24M
T/O241.82K	T/O Rate0.58%	Tradable Shares36.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VANI","market":"US","secType":"STK","nameCN":"Vivani Medical, Inc.","latestPrice":1.13,"timestamp":1781553600000,"preClose":1.1,"halted":0,"volume":214340,"hourTrading":{"tag":"盘后","latestPrice":1.17,"preClose":1.13,"latestTime":"19:15 EDT","volume":2246,"amount":2625.7898406,"timestamp":1781565358440,"change":0.04,"changeRate":0.035398,"amplitude":0.044248},"delay":0,"changeRate":0.027272727272727094,"floatShares":36870100,"shares":86235104,"eps":-0.398941,"marketStatus":"Post-Mkt","change":0.03,"latestTime":"06-15 19:28:21 EDT","open":1.17,"high":1.19,"low":1.1,"amount":241816.11599599998,"amplitude":0.081818,"askPrice":1.2,"askSize":41,"bidPrice":1.07,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.398941,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1781568000000},"marketStatusCode":4,"adr":0,"listingDate":1416373200000,"exchange":"NASDAQ","adjPreClose":1.1,"preHourTrading":{"tag":"盘前","latestPrice":1.15,"preClose":1.1,"latestTime":"09:29 EDT","volume":858,"amount":958.7913192,"timestamp":1781530199200,"change":0.05,"changeRate":0.045455,"amplitude":0.072636},"postHourTrading":{"tag":"盘后","latestPrice":1.17,"preClose":1.13,"latestTime":"19:15 EDT","volume":2246,"amount":2625.7898406,"timestamp":1781565358440,"change":0.04,"changeRate":0.035398,"amplitude":0.044248},"volumeRatio":1.927612,"impliedVol":1.117,"impliedVolPercentile":0.4422},"requestUrl":"/m/hq/s/VANI","defaultTab":"news","newsList":[{"id":"2640628163","title":"Vivani Medical publishes investor presentation on NanoPortal long-acting GLP-1 implant strategy for obesity market","url":"https://stock-news.laohu8.com/highlight/detail?id=2640628163","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640628163?lang=en_us&edition=fundamental","pubTime":"2026-06-04 22:07","pubTimestamp":1780582036,"startTime":"0","endTime":"0","summary":"Vivani outlined its NanoPortal ultra long-acting, removable subdermal GLP-1 implant platform targeting once- or twice-yearly dosing.Lead candidate NPM-139, a semaglutide implant for chronic weight management, is slated to start its clinical program in mid-2026.LIBERATE-1 first-in-human data met primary objectives on safety, tolerability, device performance, pharmacokinetics; no serious adverse events reported.Global GLP-1 market cited at USD 132 billion in 2025 sales; Morgan Stanley estimate cited at about USD 190 billion by 2035.Cash runway expected to fund the current operating plan through 1H2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on Jun","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL8ZbN8c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051108.HKD","LU1074936037.SGD","LU1988902786.USD","LU1732799900.SGD","BK4516","IE00BZ1G4Q59.USD","BK4082","IE00BKVL7J92.USD","BK4585","LU0912757837.SGD","LU1162221912.USD","LU1791710400.SGD","LU2089283258.USD","LU2133065610.SGD","BK4534","LU0006306889.USD","LU0106261372.USD","LU2347655156.SGD","LU0053666078.USD","LU0528227936.USD","LU0267386448.USD","LU1668664300.SGD","BK4504","LU0971096721.USD","LU1548497426.USD","LU0210528500.USD","LU1363072403.SGD","LU0225283273.USD","LU0390134368.USD","LU1989772840.SGD","LU0795875086.SGD","LU2271345857.HKD","LU0320765646.SGD","LU1720051017.SGD","BK4581","LU1244550577.SGD","LU0882574139.USD","LU0314104364.USD","LU2089284900.SGD","LU2264538146.SGD","LU0557290698.USD","LU2023251221.USD","LU0795875169.SGD","LU1244550221.USD","LU0098860793.USD","LU1244550494.USD","LU1732800096.USD","BK4127","LU0106831901.USD","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638469321","title":"Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2638469321","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638469321?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:30","pubTimestamp":1779971400,"startTime":"0","endTime":"0","summary":"ALAMEDA, Calif., May  28, 2026  (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3302857/0/en/Vivani-Medical-CEO-Adam-Mendelsohn-to-Present-at-the-Jefferies-Global-Healthcare-Conference-on-June-4-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","BK4585","LU0128526141.USD","XLV","BK4588","LABU","LU0029874061.USD","BK4137","VANI","XBI","BK4581","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636856294","title":"Vivani Medical director Gregg Williams acquires common shares worth $1,999,999.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2636856294","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636856294?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:31","pubTimestamp":1779193918,"startTime":"0","endTime":"0","summary":"Vivani Medical: Director Gregg Williams reported an indirect purchase of 1,587,301 common shares at USD 1.26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDLkPYWY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vivani Medical director Gregg Williams acquires common shares worth $1,999,999.26","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635756766","title":"Vivani Medical Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635756766","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635756766?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:06","pubTimestamp":1778706416,"startTime":"0","endTime":"0","summary":"Vivani Medical Inc reports results for the quarter ended March 31 - Earnings SummaryVivani Medical Inc VANI.OQ reported a quarterly adjusted loss of 9 cents per share for the quarter ended March 31, h","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q2VJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753687","title":"Vivani Medical Q1 FY26 net loss widens 7.59% to $6.78 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753687","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753687?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:13","pubTimestamp":1778703232,"startTime":"0","endTime":"0","summary":"Vivani Medical posted a Q1 net loss of USD 6.78 million, widening from USD 6.3 million a year earlier; loss per share narrowed to USD 0.08 from USD 0.11.R&D expense rose 4% to USD 4.39 million, while G&A increased 4% to USD 2.43 million.Cash and cash equivalents climbed to USD 19.75 million at March 31 from USD 16.23 million at Dec. 31, with USD 28 million in cash, cash equivalents, restricted cash and capital commitments expected to fund operations through the first half of 2027.SLIM-1 Phase 1 trial of NPM-139 semaglutide implant remains on track to start mid-2026 in Australia, with top-line results expected by end-2026 and a Phase 2 launch targeted for 2027 following a pre-IND meeting and IND filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL6TYnz3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","BK4082","SG9999014021.USD","BK4588","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210149790.SGD","VANI","IE00BN0W2W23.USD","LU2210150020.SGD","LU0314104364.USD","SG9999014013.SGD","IE00BKPKM429.USD","NDAQ","SG9999014039.USD","BK4112","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758298","title":"BRIEF-Vivani Medical Q1 Net Income USD -6.78 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758298","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758298?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702746,"startTime":"0","endTime":"0","summary":"BRIEF-Vivani Medical Q1 Net Income USD -6.78 Million\n\n\nMay 13 (Reuters) - Vivani Medical Q1 income from operations USD -6.817 million.\n\nQ1 operating expenses USD 6.817 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLX0CB913:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635759388","title":"Vivani Medical Q1 EPS USD -0.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2635759388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635759388?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLX0CB913:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758759","title":"Press Release: Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758759","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758759?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702700,"startTime":"0","endTime":"0","summary":"Initiation of SLIM-1 clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026. $28 million in cash, cash equivalents, restricted cash and capital commitments expected to fund current operating plan through the first half of 2027. ALAMEDA, Calif., May 13, 2026  -- Vivani Medical, Inc.  , a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants utilizing its proprietary NanoPortal technology, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.The Company plans to continue exploring opportunities for Vivani's stockholders to potentially realize value in its neuromodulation assets. Cortigent Inc. , a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4022","BK4588","CRGT","VANI","BK4082","BK4585","R","TM","BK4604","BK4555","BK4099","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633455847","title":"Vivani Medical Inc  expected to post a loss of 8 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633455847","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633455847?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:51","pubTimestamp":1778241067,"startTime":"0","endTime":"0","summary":"Vivani Medical Inc  expected to post a loss of8cents a share - Earnings Preview Vivani Medical Inc VANI.OQ VANI.O is expected to  show no change in quarterly revenue when it reports  results on May 11","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L16I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631529271","title":"Vivani Medical announces annual shareholder meeting via online webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2631529271","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631529271?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:37","pubTimestamp":1777495026,"startTime":"0","endTime":"0","summary":"Vivani Medical scheduled 2026 annual stockholder meeting for June 24, 2026, to be held online.Shareholders will vote on election of six directors, including independent director nominee August Moretti.Meeting will also consider adoption of amended and restated 2022 Omnibus Incentive Plan, including an 11,000,000-share increase in plan share reserve.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL5PKBNp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627291135","title":"Vivani Medical director Gregg Williams acquires common shares worth $2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2627291135","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627291135?lang=en_us&edition=fundamental","pubTime":"2026-04-16 18:30","pubTimestamp":1776335450,"startTime":"0","endTime":"0","summary":"Vivani Medical director Gregg Williams, also a 10% owner, reported purchase of 1,587,301 common shares at USD 1.26 each.Beneficial ownership rose to 32,944,484 shares held indirectly following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL9RfBTW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vivani Medical director Gregg Williams acquires common shares worth $2 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624564272","title":"Vivani Medical Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2624564272","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624564272?lang=en_us&edition=fundamental","pubTime":"2026-04-01 14:02","pubTimestamp":1775023320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VANI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2026 02:02 ET (06:02 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624535227","title":"Vivani Medical price target lowered to $3.50 from $4 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2624535227","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624535227?lang=en_us&edition=fundamental","pubTime":"2026-03-31 23:51","pubTimestamp":1774972313,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Vivani Medical (VANI) to $3.50 from $4 and keeps a Buy rating on the shares afte...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vivani-medical-price-target-lowered-to-3-50-from-4-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vivani-medical-price-target-lowered-to-3-50-from-4-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622162803","title":"Vivani Medical Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622162803","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622162803?lang=en_us&edition=fundamental","pubTime":"2026-03-28 05:03","pubTimestamp":1774645394,"startTime":"0","endTime":"0","summary":"Vivani Medical Inc reports results for the quarter ended December 31 - Earnings SummaryVivani Medical Inc VANI.OQ reported a quarterly adjusted loss of 9 cents per share for the quarter ended December","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F23E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622740899","title":"Vivani Medical Q4 EPS $(0.09) Beats $(0.10) Estimate.","url":"https://stock-news.laohu8.com/highlight/detail?id=2622740899","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622740899?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:49","pubTimestamp":1774558173,"startTime":"0","endTime":"0","summary":"Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 10 percent. This is a 18.18 percent increase over losses of $(0.11) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51496998/vivani-medical-q4-eps-0-09-beats-0-10-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vivani Medical Q4 EPS $(0.09) Beats $(0.10) Estimate.","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896708","title":"Vivani Medical FY2025 net loss widens 13.2% to $26.6 million; loss per share holds at $0.43","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896708","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896708?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:18","pubTimestamp":1774556339,"startTime":"0","endTime":"0","summary":"Vivani published a press release reporting Q4 and full-year 2025 financial results and a business update .Q4 net loss was USD 6.6 million, while R&D expense rose 7% to USD 4.6 million.FY net loss was USD 26.6 million and R&D expense increased 15% to USD 18.1 million, driven by higher clinical-trial and development spending in the biopharm division.FY G&A expense increased 6% to USD 9.4 million, primarily due to higher professional services costs across the neurostimulation and biopharm divisions.Cash and cash equivalents were USD 16.2 million at year-end, and management said cash, equivalents and commitments are expected to fund operations into mid-2027 as it targets initiation of a Phase 1 feasibility study of NPM-139 in mid-2026 with results anticipated by the end of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLqfJV9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619635451","title":"Vivani Medical Director Gregg Williams reports acquisition of Vivani Medical common shares worth USD 1.68 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2619635451","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619635451?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:16","pubTimestamp":1773656183,"startTime":"0","endTime":"0","summary":"Gregg Williams, a director and 10% owner of Vivani Medical, reported acquiring 1,575,231 common shares through private purchase transactions. The shares were acquired at prices of USD 1.03 and USD 1.26 per share. Following the acquisitions, Williams reported indirect beneficial ownership of 31,357,183 common shares. Williams also reported direct ownership of 4,799,200 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL46pdFR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vivani Medical Director Gregg Williams reports acquisition of Vivani Medical common shares worth USD 1.68 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VANI","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612135456","title":"Director and 10% Owner Gregg Williams Acquires Common Shares of Vivani Medical Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2612135456","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612135456?lang=en_us&edition=fundamental","pubTime":"2026-02-17 19:12","pubTimestamp":1771326752,"startTime":"0","endTime":"0","summary":"Gregg Williams, a director and 10% owner, reported the acquisition of common shares of Vivani Medical Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL8sqKNR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director and 10% Owner Gregg Williams Acquires Common Shares of Vivani Medical Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607084077","title":"Cortigent Reports Promising Six-Year Results for Orion Visual Prosthesis","url":"https://stock-news.laohu8.com/highlight/detail?id=2607084077","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607084077?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:30","pubTimestamp":1769689849,"startTime":"0","endTime":"0","summary":"Vivani Medical Inc. announced that its wholly-owned subsidiary, Cortigent, Inc., presented promising six-year early feasibility study results for the Orion Visual Cortical Prosthesis System at the North American Neuromodulation Society annual meeting. Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology and is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind. In addition to the Orion system, Cortigent is developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL35NhpV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014021.USD","BK4082","CRGT","BK4585","NDAQ","SG9999014013.SGD","SG9999014039.USD","LU2210150020.SGD","BK4112","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","VANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606715710","title":"Vivani Medical Director and 10% Owner Gregg Williams Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2606715710","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606715710?lang=en_us&edition=fundamental","pubTime":"2026-01-28 23:01","pubTimestamp":1769612515,"startTime":"0","endTime":"0","summary":"Gregg Williams, a Director and 10% Owner of Vivani Medical Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL1dTSSC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vivani Medical Director and 10% Owner Gregg Williams Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","VANI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vivani.com;investors.vivani.com","stockEarnings":[{"period":"1week","weight":-0.0678},{"period":"1month","weight":-0.0517},{"period":"3month","weight":0},{"period":"6month","weight":-0.1852},{"period":"1year","weight":-0.0756},{"period":"ytd","weight":-0.1057}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":-0.013761},{"month":2,"riseRate":0.333333,"avgChangeRate":0.262607},{"month":3,"riseRate":0.333333,"avgChangeRate":0.172227},{"month":4,"riseRate":0.416667,"avgChangeRate":0.031848},{"month":5,"riseRate":0.5,"avgChangeRate":0.041822},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.061344},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.022536},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.10962},{"month":9,"riseRate":0.636364,"avgChangeRate":-0.039438},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.074632},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.062683},{"month":12,"riseRate":0.333333,"avgChangeRate":0.011596}],"exchange":"NASDAQ","name":"Vivani Medical, Inc.","nameEN":"Vivani Medical, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vivani Medical, Inc.(VANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vivani Medical, Inc.(VANI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vivani Medical, Inc.,VANI,Vivani Medical, Inc.股票,Vivani Medical, Inc.股票老虎,Vivani Medical, Inc.股票老虎国际,Vivani Medical, Inc.行情,Vivani Medical, Inc.股票行情,Vivani Medical, Inc.股价,Vivani Medical, Inc.股市,Vivani Medical, Inc.股票价格,Vivani Medical, Inc.股票交易,Vivani Medical, Inc.股票购买,Vivani Medical, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vivani Medical, Inc.(VANI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vivani Medical, Inc.(VANI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}